PRTG News and Press, Portage Biotech Inc. From 11/22/21

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer tre...

Data presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Connective Tissue Oncology Society (CTOS) Annual Meeting suggest INT230-6 (PORT-1) offers a promising approach to treating metastatic disease, including advanced soft tissue sarcomas Data from I...

WESTPORT, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer tre...

WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today anno...

- $29 million raised during quarter with broad institutional support - Proceeds will accelerate advancement of clinical pipeline toward multiple data readouts over the next 18-24 months WESTPORT, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (&...

WESTPORT, Conn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following...

Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancer PORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1 antibodies WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage...

Portage Biotech (PRTG): FY GAAP EPS of -$1.35.As of June 30, 2021, the Company had approximately $28.6 million of cash on hand.Press Release For further details see: Portage Biotech reports FY results

-  Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets -  Additional clinical milestones and company progress anticipated throughout 2H 2021 and 2022 ...

Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to...